• Perioperative blood loss and inflammatory response can significantly affect recovery after surgery.
Essentials
• Perioperative blood loss and inflammatory response can significantly affect recovery after surgery.
• We studied the effects of multiple-dose oral tranexamic acid on blood loss and inflammatory response.
• A postoperative four-dose regimen brought about maximum reduction in postoperative blood loss.
• A postoperative four-dose regimen reduced inflammatory response and promoted early rehabilitation.
Summary. Background: Tranexamic acid (TXA) can reduce blood loss and the inflammatory response at multiple doses in total knee arthroplasty patients. However, the optimal regimen has not been determined. Objectives: To identify the most effective regimen for achieving maximum reductions in blood loss and the inflammatory response. Patients/Methods: Two hundred and seventyfive patients were randomized to receive a placebo (group A), a single 2-g oral dose of TXA 2 h preoperatively followed by 1 g of oral TXA 3 h postoperatively (group B), a single dose followed by 1 g of oral TXA 3 h and 7 h postoperatively (group C), a single dose followed by 1 g of oral TXA 3 h, 7 h and 11 h postoperatively (group D), or a single dose followed by 1 g of oral TXA 3 h, 7 h, 11 h and 15 h postoperatively (group E). The primary outcome was total blood loss on postoperative day (POD) 3. Secondary outcomes included a decrease in the hemoglobin level, coagulation parameters, inflammatory marker levels, and thromboembolic complications. Results: Groups D and E had significantly lower blood loss and smaller decreases in hemoglobin level than groups A, B, and C, with no significant difference on POD 3 between groups D and E. Significantly enhanced coagulation was identified for the four multiple-dose regimens; however, all thromboelastographic parameters remained within normal ranges. Group E had the lowest inflammatory marker levels and pain, and the greatest range of motion. No thromboembolic complications were identified. Conclusion: The four-dose regimen yielded the
Introduction
Tremendous progress has been made in relieving pain, reducing blood loss and ensuring fast recovery of functional performance after total knee arthroplasty (TKA) [1] [2] [3] . However, despite the multimodal analgesic and blood-salvaging approaches, substantial blood loss and excessive surgical stress responses remain essential issues in TKA, resulting in increased risks of transfusion and transfusionrelated complications, pain, and delayed rehabilitation [4] [5] [6] [7] . Thus, finding effective methods for minimizing perioperative blood loss and simultaneously reducing surgical stress-induced immune reactions is important.
The major causes of bleeding can be attributed to surgical trauma, which induces activation of both local fibrinolysis and the coagulation cascade [3, 7, 8] . Tranexamic acid (TXA) can inhibit fibrinolysis by blocking the lysinebinding sites on plasminogen [9, 10] . The efficacy and safety of TXA, administered intravenously, intra-articularly, orally, or via a combination of these routes, have been established in numerous meta-analyses [11] [12] [13] [14] . Our randomized controlled trial (RCT) demonstrated that 2 g of oral TXA administered 2 h preoperatively produced equivalent reductions in blood loss and hemoglobin (Hb) as 20 mg kg À1 of intravenous TXA administered 5 min preoperatively or 2 g of intra-articular TXA administered intraoperatively, with a great cost-saving benefit and greater ease of drug administration [15] . Moreover, several meta-analyses have indicated that oral TXA is equivalent to intravenous TXA regarding blood-sparing efficacy [13, 16] . TXA also has anti-inflammatory properties at higher or multiple doses, owing to its inhibition of plasmin, as determined in cardiac and orthopedic surgery [17] [18] [19] . The fibrinolytic and inflammatory reaction elicited by surgical trauma may affect hemostasis and postoperative pain to a greater extent than the surgery itself [20] [21] [22] . Thus, it may be beneficial to prolong antifibrinolytic and anti-inflammatory treatment during the postoperative period [23] . Additionally, it has been shown that multiple boluses of intravenous or oral TXA can effectively reduce bleeding and inflammatory responses in TKA patients [17, 24] . However, the TXA dosage regimens in these and many other studies were not based on pharmacokinetic modeling [25] . Moreover, little is known about the optimal dosing, timing, duration and pharmacokinetics of oral TXA in TKA patients. It is critical to determine the optimum regimen of oral TXA to maximize the efficacy of hemostatic action and to minimize side effects. The objective of this RCT, conducted on the basis of pharmacokinetic modeling of oral TXA, was to assess the additional effects of multiple doses of oral TXA on hemostasis, thrombosis, and inflammation, and to identify its most effective regimen in TKA patients.
Materials and methods

Study design
After approval had been obtained from the Clinical Trials and Biomedical Ethics Committee of Sichuan University (No. 201302008), this RCT was registered with the Chinese Clinical Trial Registry (ChiCTR-IPR-17011847). This trial was conducted in accordance with the principles of the Helsinki Declarations, and we followed the Consolidated Standards for Reporting of Trials (CONSORT) recommendations for reporting RCTs [26] . All patients provided written informed consent.
Study participants
From September 2017 to March 2018, consecutive adult patients who were diagnosed with knee osteoarthritis and scheduled for unilateral, primary TKA were screened for inclusion. Patients were excluded if they had: known allergic reactions to TXA; a history of deep vein thrombosis (DVT) or pulmonary embolism (PE); an Hb level of < 110 g L
À1
; a serum albumin level of < 35 g L
; an acquired or congenital coagulopathy; a history of an arterial thromboembolic event, cardiac bypass surgery or placement of an arterial stent within the past year; a history of high-risk medical comorbidities; or received anticoagulant therapy (warfarin or heparin) within the previous week. We also excluded patients who declined to receive blood products.
Treatment regimens, blinding, and randomization
The enrolled subjects were randomized to one of five interventions: group A received 2 g of an oral form of placebo (500 mg, each tablet) approximately 2 h preoperatively, and then 1 g orally of placebo 3 h, 7 h, 11 h and 15 h postoperatively; group B received 2 g of oral TXA (500 mg, each tablet) 2 h preoperatively, and then 1 g of oral TXA 3 h postperatively and 1 g of placebo 7 h, 11 h and 15 h postoperatively; group C received 2 g of oral TXA 2 h preoperatively, and then 1 g of oral TXA 3 h and 7 h postoperatively, and 1 g of placebo 11 h and 15 h postoperatively; group D received 2 g of oral TXA 2 h preoperatively, and then 1 g of oral TXA 3 , 7 h and 11 h postoperatively, and 1 g of placebo 15 h postoperatively; group E received 2 g of oral TXA 2 h preoperatively, and then 1 g of oral TXA 3 h, 7 h, 11 h and 15 h postoperatively. All patients received 1.5 g of TXA diluted in 50 mL of saline solution administered intra-articularly, on the basis of our previous study [27] . The study medications and placebo pills (starch tablet) were identical in appearance.
A random allocation sequence was computer-generated by the use of Randomization.com, and the unique randomization numbers were placed into sequentially numbered opaque sealed envelopes. These envelopes could be identified only from the randomization code, which was known only to the independent pharmacologist. Just prior to surgery, an envelope was opened randomly by a research pharmacologist, who also prepared the study medication to ensure identical appearance and blinding. This information was linked to a confidential database by an independent statistician. The patients, surgeons and their team members and endpoint adjudicators were blinded to allocation until the final data analysis.
Surgery and postoperative protocol
One senior orthopedic surgeon performed or supervised all of the operations, which were performed under general anesthesia. A midline skin incision with a medial parapatellar approach was used, and the patella was routinely resurfaced. A posterior-stabilized cemented prosthesis (Depuy Synthes, Warsaw, IN, USA) was implanted. No tourniquets or postoperative drains were used. At the end of surgery, a compressive dressing and a cooling device were applied.
All patients were managed according to the same perioperative protocols [28] . Patients were offered the usual standardized anesthesia, consisting of periarticular injection of ropivacaine (0.2%) perioperatively [29, 30] and oral administration of celecoxib (200 mg twice daily; Pfizer, New York, USA) and enteric-coated diclofenac sodium (50 mg twice daily; Novartis, Basel, Switzerland) at the same time (i.e. 8:00 a.m. and 5:00 p.m.) postoperatively during hospitalization [17, 31] .
Patients received: mechanical thromboprophylaxis through an intermittent inflatable lower-extremity pump on the day after surgery; and physiotherapy, including lower-extremity strength training, mechanical ankle pumping exercises, and range of motion (ROM) exercises. Intermittent pneumatic compression was performed until weight-bearing was allowed. Patients also received chemical thromboprophylaxis with low molecular weight heparin. It was used beginning (2000 AxaIU; Clexane [enoxaparin sodium], administered subcutaneously) 8 h postoperatively, and was continued once daily (4000 IU) during hospitalization. Rivaroxaban (10 mg, administered orally; Bayer, Leverkusen, Germany) was continued for 10 days after discharge [24, 28] .
Blood transfusions were given to patients according to the perioperative transfusion guidelines of the Chinese Ministry of Health [32] . Allogeneic blood transfusion was administered to any patient with an Hb level of < 70 g L À1 who was asymptomatic or who developed intolerable symptoms of anemia or any organ dysfunction related to anemia regardless of Hb level.
Study parameters
Patient demographic and preoperative characteristics were collected for comparison. The primary outcome was total blood loss determined by the difference between the initial preoperative hematocrit and the hematocrit on postoperative day (POD) 3, according to equations described by Gross et al. [33] . The total blood loss was calculated with the formula described by Nadler et al. [34] (Data S1). The secondary outcomes included hidden blood loss (HBL), platelet count (PLT), decrease in Hb, and intraoperative blood loss. Other secondary outcomes included blood transfusion, hospital stay, patient-rated knee pain, knee circumference, active range of motion (measured with a goniometer), and Hospital for Special Surgery score. Intraoperative blood loss was calculated by measuring suction drain contents and weighing gauzes [35] . HBL was calculated as the estimated total blood loss minus the intraoperative blood loss, as described in previous studies [1, 35] . Knee pain at rest and with 45°knee flexion was determined by use of a 100-mm visual analog scale (0, no pain; 100, worst pain). Knee circumference (local inflammation) encompassing the upper and lower poles of the patella was measured on POD 1, POD 2, and POD 3 [1] .
The concentrations of inflammatory markers (C-reactive protein [CRP] and interleukin [IL]-6) and erythrocyte sedimentation rate (ESR) were measured preoperatively and at 6 h, 10 h, 14 h, 24 h, 32 h and 48 h postoperatively. CRP levels were measured with standard commercial rate-nephelometry kits (High Sensitivity C-Reactive Protein Reagent) and analyzed by means of IMMAGE immunochemical system software (Beckman IMMAGE 800, Brea, CA, USA). Each estimation of IL-6 was performed with standard electrochemiluminescence immunoassay kits (specific mAb R1 reagent) and analyzed on a validated MODULAR ANALYTICS platform (Roche E170; Basel, Switzerland). ESR was measured with the Westergren method by use of an Automated Erythrocyte Sedimentation Rate Analyzer (Electa Lab, Forli, Italy). All collected EDTA-blood samples were labeled without patient identification and immediately analyzed. All intraassay and interassay coefficients of variation (CVs) were provided by the manufacturer (intra-assay and interassay CVs: 3.11-4.89% and 3.88-5.17% for CRP, 0.9-2.9% and 1.18-3.28% for IL-6, and 3.21-4.22% and 3.65-5.78% for ESR, respectively). All measurements were performed by the Department of Laboratory Medicine certificated by Clinic American Pathology.
A 2-mL blood sample was required for thromboelastographic (TEG) assessment, and was analyzed immediately. [36] . Blood samples for TEG analyses were activated with kaolin as a coagulation activator, and processed within 1 h of blood draw at 37°C in a stationary cylindrical cup [37] . The rotation movement of the pin was converted to an electrical signal, which can be displayed as a typical TEG trace by use of a computerized coagulation analyser (TEG5000; Haemoscope, Niles, IL, USA) [37] . The TXA concentration was also measured at each time point with tandem liquid chromatography mass spectrometry [36] .
Thromboembolic complications and other complications were also noted. During hospitalization, patients were examined daily for clinical symptoms of DVT. A diagnostic Doppler ultrasound examination of both legs was routinely performed on POD 3 and POD 7 and during the 3-month follow-up. If patients had symptoms or signs suggestive of DVT or PE, ultrasound examination and enhanced computed tomography pulmonary arteriography were immediately performed [1] .
Statistical analysis
Continuous-variable data were evaluated for a normal distribution with the Kolmogorov-Smirnov test. They are presented as the means and standard deviations (SDs) (normalized data) or median and interquartile ranges (non-normalized data). Categorical variables are presented as counts. One-way ANOVA with a post hoc Tukey's test was used to compare normally distributed continuous variables, and the Kruskal-Wallis with a post hoc Nemenyi test was applied to compare skewed continuous variables [24] . Moreover, repeated measurement regression with random intercepts and first-order autocorrelation was used to test continuous data with repeated measures. Categorical data were tested with the chi-square test or Fisher's exact test. Significance was set at 5%, and all tests were two-sided (P < 0.05). All analyses were performed with SPSS version 21.0 (SPSS, Chicago, IL, USA).
The sample size was determined on the basis of the primary outcome, which was total blood loss on POD 3. On the basis of the preliminary data at our institution, a 162-mL reduction in POD 3 total blood loss was considered to be clinically important. We assumed an SD of 212 mL for blood loss, an a of 5%, a power of 85%, and a 20% dropout rate. Thus, it was determined that a minimum of 55 patients per arm were required.
Results
Subjects
A total of 344 patients were assessed for eligibility. Of these, 69 were excluded, for the following reasons: 32 did not meet the inclusion criteria, eight declined to participate, 24 underwent revision surgery, and five refused to receive blood products. Thus, the remaining 275 eligible participants were randomized to receive study medication and distributed homogeneously between five groups (55 patients per group; groups A, B, C, D, and E; Fig. 1 ). The duration of follow-up was 3 months, and no patient was lost during the follow-up period. Patient demographic characteristics and perioperative variables were comparable among the groups (Tables 1 and 2) . . Group E had a higher PLT than group C, and there was no difference between groups D and E ( Table 2 ). Groups B, C, D and E had significantly lower intraoperative blood loss than group A, whereas no difference was found among the former four groups.
Study outcomes
According to the TEG analysis, groups B, C, D and E had significantly reduced R, k, and LY30, and increased MA and a-angle, as compared with group A. As compared with group A, groups B, C, D and E showed enhanced coagulation with an increasing CI, which indicated increased overall coagulation status (Fig. 2) . The CI increased from the intraoperative period and peaked at 24 h postoperatively. Group E had a significantly higher CI than groups B, C and D from 24 h to 48 h postoperatively, which indicated the most prolonged coagulant function. Multiple doses of oral TXA (groups B, C, D, and E) extended the time of coagulant function, without increasing the peak values during the assessed period; the mean TEG parameters remained within their normal ranges.
The serum CRP levels in groups D and E were lower than in group A at every time point within 32 h postoperatively, and group E had lower serum CRP levels than group D at 24 h and 32 h postoperatively (Fig. 3) . Groups D and E had significantly lower serum ESR levels than group A at 6 h, 10 h, 14 h and 24 h postoperatively, and group E had the lowest serum ESR level. No significant differences were detected among groups at 48 h postoperatively. Moreover, groups D and E had significantly lower serum IL-6 levels than groups A and B at 10 h, 14 h and 24 h postoperatively (Fig. 3) . The serum IL-6 level was significantly lower in group E than in group D at 24 h and 32 h postoperatively.
The differences in pain among groups were significant on POD 1, POD 2, and POD 3, and group E had the lowest pain at every time point within three postoperative days (Fig. 4) . The knee circumference was significantly lower in groups D and E than in groups A and B. However, no significant difference was detected between groups D and E. Moreover, group E had significantly greater ROM than groups A, B, and C. ROM was significantly greater in group E than in group D on POD 1, whereas no difference was observed on POD 2 and POD 3 (Fig. 4) . The transfusions and hospital stays were similar among the groups. The incidence of adverse events was extremely low, with no notable differences. No PEs or DVTs were observed in any group (Table 3) .
The minimal plasma TXA concentration required to maintain a hemostatic effect in vivo is 10 mg L À1 [38, 39] .
A single 2-g dose of oral TXA achieved a therapeutic effect approximately 2 h after administration. Groups B, C, D and E maintained levels above the therapeutic threshold for approximately 10 h, 14 h, 18 h and 22 h after receiving oral TXA, respectively ( Figure S1 . All TXA was eliminated by 48 h after surgery (Data S1).
Discussion
The major finding of our study was that multiple doses of oral TXA led to a 19.2-57.6% reduction in total blood Hb, hemoglobin; PLT, platelet count; POD, postoperative day; SD, standard deviation. Hidden blood loss was calculated as the estimated total blood loss minus the intraoperative blood loss. *Significantly different (P < 0.05) between groups A and B. †Significantly different (P < 0.05) between groups A and C. ‡Significantly different (P < 0.05) between groups A and D. §Significantly different (P < 0.05) between groups A and E. ¶Significantly different (P < 0.05) between groups B and C. **Significantly different (P < 0.05) between groups B and D. † †Significantly different (P < 0.05) between groups B and E. ‡ ‡Significantly different (P < 0.05) between groups C and D. § §Significantly different (P < 0.05) between groups C and E. ¶ ¶Significantly different (P < 0.05) between groups D and E. Fig. 2 . Perioperative thromboelastographic analysis. The perioperative reaction time (R) (A), maximum amplitude (MA) (B), rate of thrombus formation (k) (C), a-angle (D), lysis rate at 30 min (LY30) (E) and coagulation index (CI) (F) of thromboelastographic analysis are shown. *Significantly different (P < 0.05) between groups A and B. †Significantly different (P < 0.05) between groups A and C. ‡Significantly different (P < 0.05) between groups A and D. §Significantly different (P < 0.05) between groups A and E. ¶Significantly different (P < 0.05) between groups B and C. **Significantly different (P < 0.05) between groups B and D. † †Significantly different (P < 0.05) between groups B and E. ‡ ‡Significantly different (P < 0.05) between groups C and D. § §Significantly different (P < 0.05) between groups C and E. ¶ ¶Significantly different (P < 0.05) between groups D and E. [Color figure can be viewed at wileyonlinelibrary.com] loss and 20.7-52.7% reductions in Hb, respectively, as compared with the placebo. The four-dose regimen corresponded to significantly less total blood loss and a lower Hb decrease than the three-dose regimen on POD 1; however, no difference in blood-saving efficacy was observed between the three-dose and four-dose regimens on POD 3. Furthermore, multiple-dose regimens can significantly prolong coagulant action and alleviate inflammatory reactions without additional thromboembolic complications, and the four-dose regimen had the most hemostatic effects.
Surgical trauma in TKA patients can induce activation of fibrinolysis [40, 41] . TXA can effectively inhibit fibrinolysis, and thereby reduce perioperative bleeding. On the basis of the levels of fibrin degradation products and Ddimer, our pilot studies and other studies have shown that fibrinolysis peaks at 6 h and remains high for at least 18 h after primary TKA [17, [42] [43] [44] . Thus, maintaining such inhibited fibrinolytic activity in the postoperative period may cover the period of high fibrinolysis and lead to the maximum reduction in blood loss. Our RCT demonstrated that multiple doses of intravenous or oral TXA were superior to a single bolus in stopping bleeding in TKA patients [18, 24] . However, no pharmacokinetic and serum analyses or concomitant coagulation monitoring were performed in these and many other studies, and the changes in coagulation and systemic absorption of TXA after such administration remain unclear. Our previous RCT demonstrated that oral TXA is simple and inexpensive as compared with intravenous and topical forms, which indicates comparable reductions in blood loss in total hip arthroplasty patients [15] , as also determined in TKA patients [28, 45] . Thus, we recommended a switch to oral TXA in an effort to reduce costs at our center. To our knowledge, this is the first study based on TEG and pharmacokinetic analysis to evaluate the effects of (Fig. 5) . According to our pharmacokinetic analysis, the administration of 2 g of oral TXA 2 h preoperatively can result in a therapeutic level by the beginning of the operation. The maintenance dose of oral TXA applied in this study was based on studies of this drug in total joint arthroplasty, in which maintenance doses range from 1 g to 2 g, delivered over a period of 1-18 h [24, 28, [45] [46] [47] . The findings from studies of the effects of maintenance doses of TXA on blood loss have indicated that there is no significant difference between low and high doses [19, 48] . Considering potential side effects (i.e. seizures) with higher dosing regimens [49] , we selected a lower dose (1 g of oral TXA) within the range to maintain the therapeutic level of TXA. Our pharmacokinetic information showed that the plasma TXA concentration remained above the hemostatic threshold (10 mg L À1 ) for approximately 10 h, 14 h, 18 h and 22 h after surgery in the patients who received the one-dose, two-dose, three-dose and four-dose regimens, respectively. According to TEG analysis, a loading dose of 2 g of oral TXA followed by a maintenance dose of 1 g of oral TXA at 4-h intervals led to plasma TXA concentrations that were sufficient to provide hemostatic benefits. Moreover, the four-dose regimen showed a significantly higher CI within 48 h postoperatively than the one-dose, two-dose and three-dose regimens. This may help to explain why the four-dose regimen showed the maximum reduction in blood loss and the minimum decrease in PLT among the multiple-dose regimens. However, no significant differences were identified in terms of postoperative blood loss and Hb decrease between the three-dose and four-dose regimens on POD 3. The three-dose and four-dose regimens significantly reduced HBL as compared with the one-dose and two-dose regimens. The mechanism of HBL was considered to be extravasation into tissue and residual blood in the joint, which result in swelling of the knee [1] . Thus, the reduced swelling of the knee observed in patients who received the three-dose and four-dose regimens may be explained by the reduction in HBL. Although the hemostatic duration in the multiple-dose regimen groups remained longer than in the placebo group, all TEG parameters remained within their normal ranges, and the multiple-dose regimens may not increase the risk of thromboembolic complications as compared with placebo. Furthermore, no thromboembolic complications were observed. The analysis was probably underpowered for detecting differences in the rates of thromboembolic complications, so large cohort studies are required. However, the safety of TXA for any dose, timing or route of administration has been confirmed in numerous meta-analyses [11, 14, 50] . Moreover, comprehensive venous thromboembolism prevention strategies may be another possible explanation for the lack of additional thromboembolic complications. The short (3-month) duration of follow-up might have concealed a different long-term safety profile for mutiple-dose regimens. However, all TXA was eliminated by 48 h after surgery, according to our pharmacokinetic analysis. Thus, the 3-month follow-up period was adequate to identify attributable adverse events.
TXA may also have an anti-inflammatory effect, owing to its inhibition of plasmin. Studies have reported that infusion of a maintenance dose of TXA in addition to the preoperative dose may provide additional anti-inflammatory benefits [19] . Moreover, multiple doses of intravenous TXA were demonstrated to have anti-inflammatory effects, as determined in our RCTs regarding total joint arthroplasty [17, 18] . This study demonstrated significant reductions in IL-6, ESR and CRP with multiple-dose regimens as compared with placebo. The anti-inflammatory effect was maintained in the postoperative 32-h period with prolonged administration of oral TXA. Our previous study reported a positive relationship between postoperative pain and inflammatory marker levels [51] , and these factors may explain why the multiple-dose regimens resulted in corresponding reductions in pain after TKA as placebo, despite an extensive multimodal analgesic approach [30, 52] . Our results showed that the fourdose regimen resulted in less knee pain and swelling, which promoted earlier exercise and ambulation, faster rehabilitation and greater ROM than the other regimens.
Our study had various strengths and limitations. The randomization methods ensured that participating researchers did not have foreknowledge of allocation. The baseline characteristics were well balanced. However, we did not include patients with a high risk of venous and arterial thrombosis and pre-existing coagulopathy. Therefore, our findings may not be applicable to these patients. Moreover, to evaluate the efficacy of these regimens, we only measured blood loss outcomes at 72 h postoperatively, because most blood loss occurred in the first 48 h postoperatively, and the TXA was eliminated by 48 h DVT, deep vein thrombosis; HSS, Hospital for Special Surgery; PE, pulmonary embolism; SD, standard deviation. *Significantly different (P < 0.05) between groups A and B. †Significantly different (P < 0.05) between groups A and C. ‡Significantly different (P < 0.05) between groups A and D. §Significantly different (P < 0.05) between groups A and E. ¶Significantly different (P < 0.05) between groups B and D. **Significantly different (P < 0.05) between groups B and E. † †Significantly different (P < 0.05) between groups C and E.
after surgery [40, 53] . Thus, we believe that the outcome measurements 72 h postoperatively should be adequate.
In conclusion, the three-dose regimen is the least necessary regimen for effective reduction in total blood loss. However, the four-dose regimen was the most effective regimen in our study, with maximum efficacy in reducing blood loss and the inflammatory response, relieving pain, and promoting early rehabilitation without an increased risk of complications. This verification of the superiority of the four-dose regimen provides ample evidence for its use in TKA patients as part of a multimodal protocol for blood loss prevention based on pharmacokinetic dosing recommendations. However, either additional studies or prospective quality assurance studies are required to ensure that the findings are reproducible. 
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